{"title":"CD1B Expression in Triple-Negative Breast Cancer: Its Implications for Prognosis and Immunotherapy Outcomes.","authors":"Hongwei Jin, Mengting Wan, Shuaikang Pan, Ziqi Wang, Wei Wang, Jinguo Zhang, Xinghua Han","doi":"10.2174/0115665232364481250131071311","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is a hallmark of triple-negative breast cancer (TNBC), which results in fewer treatment options and inferior clinical outcomes. The major histocompatibility complex family includes CD1B. By exposing T cells to lipid antigens, it alters immunological responses. Although the function of CD1B has been investigated in a number of malignancies, its relevance in TNBC has not been fully investigated.</p><p><strong>Method: </strong>In this study, immunohistochemistry (IHC) analysis of tissue samples and public databases was carried out to examine the expression of CD1B and its implications for prognosis in TNBC.</p><p><strong>Result: </strong>Compared to normal tissues, TNBC tissues demonstrated significantly higher levels of CD1B expression. Better overall survival, including survival without distant metastases and survival without recurrence, was found to be associated with higher levels. Additionally, more immune cells, primarily memory B cells and regulatory T cells, entering the TNBC region were found to be associated with greater levels of CD1B. It was found that the immunological microenvironment of TNBC was significantly affected by CD1B. The association between CD1B and immune-related pathways was also identified by examining functional enrichment. Drug sensitivity can be used to identify potential CD1B-targeting therapies. According to these results, CD1B might be a useful prognostic indicator and a possible target for treatment in TNBC.</p><p><strong>Conclusion: </strong>Nevertheless, additional experimental verification is required to verify the clinical significance of CD1B.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665232364481250131071311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is a hallmark of triple-negative breast cancer (TNBC), which results in fewer treatment options and inferior clinical outcomes. The major histocompatibility complex family includes CD1B. By exposing T cells to lipid antigens, it alters immunological responses. Although the function of CD1B has been investigated in a number of malignancies, its relevance in TNBC has not been fully investigated.
Method: In this study, immunohistochemistry (IHC) analysis of tissue samples and public databases was carried out to examine the expression of CD1B and its implications for prognosis in TNBC.
Result: Compared to normal tissues, TNBC tissues demonstrated significantly higher levels of CD1B expression. Better overall survival, including survival without distant metastases and survival without recurrence, was found to be associated with higher levels. Additionally, more immune cells, primarily memory B cells and regulatory T cells, entering the TNBC region were found to be associated with greater levels of CD1B. It was found that the immunological microenvironment of TNBC was significantly affected by CD1B. The association between CD1B and immune-related pathways was also identified by examining functional enrichment. Drug sensitivity can be used to identify potential CD1B-targeting therapies. According to these results, CD1B might be a useful prognostic indicator and a possible target for treatment in TNBC.
Conclusion: Nevertheless, additional experimental verification is required to verify the clinical significance of CD1B.
期刊介绍：
Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases.
Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
